Navigation Links
Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
Date:1/31/2008

VAP Cholesterol test can help doctors and clinicians identify best

treatment options for patients at risk of heart disease

BIRMINGHAM, Ala., Jan. 31 /PRNewswire/ -- Clinical trial results from a new cholesterol-fighting drug combination point to the need for more detailed cholesterol testing, including direct measurement of LDL and other lipids. That's according to Atherotech, a cardio-diagnostic company that has developed an expanded cholesterol test called the VAP (Vertical Auto Profile) test, which can help doctors and clinicians identify the best treatment options for patients at risk of heart disease.

According to Atherotech Chief Medical Officer James Ehrlich, M.D., media reports about recently released trials have now resulted in widespread concern and confusion about the general value of lipid lowering agents, particularly statins, which play a critically important role in very high risk patients. Ehrlich pointed to a recent BusinessWeek article that raised multiple questions about the role of statins in the prevention of coronary disease, the nation's top killer.

"Atherotech believes that precise physician decisions about lifelong management of hypercholesterolemia can only be accomplished with a detailed profiling of lipoprotein components," said Atherotech Chief Medical Officer James Ehrlich, M.D. "By identifying the patient's true risk and by detailing his/her lipid profile with a VAP test, the physician can now successfully modify risk and improve the lipid levels in a rational manner. Some patients need combination therapy while others are well treated with monotherapy (statins)."

Ehrlich explained that new drugs and therapies are still important tools in helping individuals at risk to reach LDL goals, sometimes without statin therapy. However, he emphasized how we modify lipoprotein patterns may be more important in decreasing the risk of heart attack and stroke than simply lowering LDL cholesterol alone
'/>"/>

SOURCE Atherotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
2. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
3. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
4. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
5. Difficult to Treat Erectile Dysfunction Patients
6. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
7. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
10. A Must Read for Breast Cancer Patients
11. Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...swire/ -- Biotech firm Replikins Ltd., which has a... pandemic through the prediction, outbreak, and pr...its latest biochemical analysis of the virus. The ...ine Flu") virus has dropped from its peak of 3.7 (...he spring of 2009 to resting non-epidemic levels t...
(Date:11/25/2009)...wire/ - Cytochroma today announced the appointment.... Moldt will replace Mr. Ulrik Spork as the Novo A...er of Board members remains unchanged at six membe...ldt to the board and look forward to benefiting fr...nues to make progress in becoming a leading CKD-fo...
(Date:11/25/2009)...ire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq:...m.D., president and chief executive officer, will ...re Conference. , ,Presentation details are as fol...rence,Date: Tuesday, December 1, 2009,Time: ... Palace Hotel, New York, NY,Webcast: <a href=,h...
(Date:11/24/2009)...also Visit Detroit , (Voc...ench Ambassador for International Investment, and ... , , ,What: Ambassador Appia is available to meet...ives adopted by France to further develop the fina...n and development., , ,When: Available for Intervi...
Breaking Biology Technology:Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Cytochroma Announces Appointment of Peter Moldt to Board of Directors 2Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...Soliris(R) Sales Reflect Strong 2007 Launch; Posit... U.S. and International Markets, Fourth Quarter...ulizumab) net product sales were $33.9 million in ... million in Q3 2007., * Q4 GAAP net loss was $12....AP net loss of $20.1 million, or $0.55 per share, ...
...Three-Year Extension for Integrated Drug Discovery...s for the Treatment of Huntington Disease, HAMBUR...ornia, February,14 Evotec AG (Frankfurt Stock Exc...Inc., a not-for-profit organization,pursuing a bio...Disease,(HD), has extended its collaboration with ...
..., Nanotechnology researchers are developing the p...able to generate electricity to power small electr... others whose physical motion could be harnessed a... 14 issue of the journal Nature details how pairs ...s can generate electrical current using the piezoe...
Other Biology Technology:Alexion Reports Fourth Quarter and Full Year 2007 Results 2Alexion Reports Fourth Quarter and Full Year 2007 Results 3Alexion Reports Fourth Quarter and Full Year 2007 Results 4Alexion Reports Fourth Quarter and Full Year 2007 Results 5Alexion Reports Fourth Quarter and Full Year 2007 Results 6Alexion Reports Fourth Quarter and Full Year 2007 Results 7Alexion Reports Fourth Quarter and Full Year 2007 Results 8Alexion Reports Fourth Quarter and Full Year 2007 Results 9Alexion Reports Fourth Quarter and Full Year 2007 Results 10Alexion Reports Fourth Quarter and Full Year 2007 Results 11Alexion Reports Fourth Quarter and Full Year 2007 Results 12Alexion Reports Fourth Quarter and Full Year 2007 Results 13Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million 2Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million 3Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million 4Fiber-based nanotechnology in clothing could harvest energy from physical movement 2Fiber-based nanotechnology in clothing could harvest energy from physical movement 3Fiber-based nanotechnology in clothing could harvest energy from physical movement 4
(Date:11/30/2009)...of lower early bird registration rates and registe...s of 2010 at http://www.iofwco-ecceo10.org/ , ...International Osteoporosis Foundation (IOF) and th...ts of Osteoporosis and Osteoarthritis (ESCEO). Mor...e expected to attend. The exciting scientific prog...
(Date:11/30/2009)...lorless and odorless radioactive gas that is produ...a product of uranium decay and is found in trace a...roundwater as well as building materials, plants, ...ion is expressed as the amount of radiation that w... a liter of air; thus the units are picocuries per...
(Date:11/26/2009).... (November 26, 2009) Whitehead researchers have ...ells to pinpoint specific genes and proteins used ... . , In most human cell cultures genes are prese...d one from the mother. Gene inactivation by mutati...is inactivated, the second copy usually remains ac...
Breaking Biology News(10 mins):Health Physics Society recommends considering action for indoor radon below current guidelines 2Knockouts in human cells point to pathogenic targets 2U S Court of Appeals Upholds AstraZeneca AWP Settlement 6446 1U S Court of Appeals Upholds AstraZeneca AWP Settlement 6446 2U S Court of Appeals Upholds AstraZeneca AWP Settlement 6446 3Spanish biotechnology should focus on food and plant sectors to be more competitive 14936 1Spanish biotechnology should focus on food and plant sectors to be more competitive 14936 2H1N1 Pandemic May Have Peaked in October in U S According to Quest Diagnostics 61864 1H1N1 Pandemic May Have Peaked in October in U S According to Quest Diagnostics 61864 2H1N1 Pandemic May Have Peaked in October in U S According to Quest Diagnostics 61864 3
... capable of metacognition—that is, they can posses...ility, which can also be thought of as the capacit...es, was previously only recognized in humans and o...n Foote and Jonathon Crystal of the University of ...iology, published by Cell Press, on March 8th. , A...
...n ovarian cancer may present a new target for diag...ccording to researchers at the University of Illin...f Pharmacy found that interfering with the product...d invasiveness of tumor cells in test-tube experim...human ovarian tumors overexpressed polypyrimidine ...
...om the lungs of transplant patients demonstrates f...de in adult organs and are not derived from bone m...ls may be able to help with the rejection of donat... , The study by University of Michigan Health Syst... number of lung transplant patients who experience...
Other Biology News:Metacognition: Faced with a test, rats can check their knowledge first 2RNA splicing factor implicated in ovarian tumor cell growth 2Type of stem cell found to reside in transplanted lungs 2Type of stem cell found to reside in transplanted lungs 3
Anti-Yersinia pestis Monoclonal Antibody, Unconjugated from ViroStat Inc.
Rabbit Anti-Olfactory Receptor LS189744 Polyclonal Antibody, Unconjugated from Abcam
Anti-Varicella-zoster Virus, Nucleocapsid Protein Monoclonal Antibody, Unconjugated from CHEMICON
Mouse Anti-Zeralenone Monoclonal Antibody, Unconjugated, Clone 11C9 from Abcam
Biology Products: